Loading
Madrigal Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 20 Aug 2025.
Madrigal Pharmaceuticals, Inc.: what insiders have been doing
Madrigal Pharmaceuticals, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). In the past year (18 October 2025 to 18 October 2026), 73 filings came from 19 insiders.
Only sales appear on the open market, 43 sales in all totalling €10.0M, filed by 5 insiders. Biggest ticket of the year: €944k, sold by Taub Rebecca and made public on 20 January 2026.
For context, the typical company on the same exchange (median of 5,458 companies) published 22 filings over the same period, against 73 filings here. The full history, which starts in 2016, counts 56 purchases against 64 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 958.4 m USD and net income at -288.3 m USD.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Elsewhere in the same sector, our signals recently picked up insider purchases at Anixa Biosciences Inc and Vivos Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
238
Thresholds
n/a
Buy Volume
€23M
56 ops. · all time
Sell Volume
€22M
64 ops. · all time
Who traded when
BuySaleWilliam John Sibold38 sales
Huntsman Carole5 sales
Kelley Shannon T5 sales
Taub Rebecca5 sales
Dier Mardi3 sales
Waltermire Robert E.3 sales
+3 other insiders
Since the insiders bought
- +26.9%Entry US$407.09 · Close at T+365 US$516.74
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Madrigal Pharmaceuticals, Inc. Strong Buy (bullish), based on 18 analysts. Average price target: US$685.78.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 19,085 of 24,148 companies
31.6
score / 100
Value27
Quality36
FCF yld-1.9%
Earn yld-2.8%
EV/EBITDA·
ROE-53%
Gross mgn94%
Net mgn-30%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$449.74
Analyst consensus
18 analystsStrong buy
US$543.00Target US$685.78(+52%)US$962.00
Income statement
RevenueUS$958.4M
Gross profitUS$902.3M94% margin
EBITDA-US$264.5M-28% margin
Net income-US$288.3M-25.3% margin
Valuation
PER (forward)46.7x
P/Book19.8x
Beta-1.05
Balance sheet & cash
Market capUS$10.4B
Total debtUS$347.6M
Free Cash Flow-US$193M
Debt / Equity66%
Profitability & ownership
ROE-53.3%
ROA-17.8%
% insiders5.8%
% institutions104.3%
Last declaration on 28 September 2026
Declarations238 total
50,000 shares@ US$516.560.22% mcap100.0% of flowCommonSEC144:0001950047-26-009840
5,221 shares@ US$533.120.023% mcap100.0% of flowCommonSEC144:0001950047-26-009360
131 shares@ US$527.87830.0006% mcap0.4% of flowCommon StockSEC:0001628280-26-061581:0
644 shares@ US$535.27190.0028% mcap2.1% of flowCommon StockSEC:0001628280-26-061581:6
1,040 shares@ US$536.11230.0046% mcap3.4% of flowCommon StockSEC:0001628280-26-061581:7
640 shares@ US$537.17380.0028% mcap2.1% of flowCommon StockSEC:0001628280-26-061581:8
520 shares@ US$538.29710.0023% mcap1.7% of flowCommon StockSEC:0001628280-26-061581:9
215 shares@ US$539.02810.0010% mcap0.7% of flowCommon StockSEC:0001628280-26-061581:10
362 shares@ US$541.65380.0016% mcap1.2% of flowCommon StockSEC:0001628280-26-061581:12
160 shares@ US$542.54750.0007% mcap0.5% of flowCommon StockSEC:0001628280-26-061581:13
761 shares@ US$544.83070.0034% mcap2.5% of flowCommon StockSEC:0001628280-26-061581:22
120 shares@ US$546.37670.0005% mcap0.4% of flowCommon StockSEC:0001628280-26-061581:23
347 shares@ US$529.26710.0015% mcap1.1% of flowCommon StockSEC:0001628280-26-061581:1
522 shares@ US$530.23110.0023% mcap1.7% of flowCommon StockSEC:0001628280-26-061581:2
368 shares@ US$531.98970.0016% mcap1.2% of flowCommon StockSEC:0001628280-26-061581:3
512 shares@ US$533.09320.0023% mcap1.7% of flowCommon StockSEC:0001628280-26-061581:4
396 shares@ US$534.19640.0017% mcap1.3% of flowCommon StockSEC:0001628280-26-061581:5
505 shares@ US$540.19090.0023% mcap1.7% of flowCommon StockSEC:0001628280-26-061581:11
60 shares@ US$533.09130.0003% mcap0.2% of flowCommon StockSEC:0001628280-26-061581:14
106 shares@ US$534.0630.0005% mcap0.3% of flowCommon StockSEC:0001628280-26-061581:15
218 shares@ US$535.94350.0010% mcap0.7% of flowCommon StockSEC:0001628280-26-061581:16
160 shares@ US$537.61750.0007% mcap0.5% of flowCommon StockSEC:0001628280-26-061581:17
687 shares@ US$540.58570.0031% mcap2.3% of flowCommon StockSEC:0001628280-26-061581:18
368 shares@ US$541.64230.0016% mcap1.2% of flowCommon StockSEC:0001628280-26-061581:19
1,202 shares@ US$542.60320.0054% mcap4.0% of flowCommon StockSEC:0001628280-26-061581:20
25 of 238 declarations
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ market (United States). The company is focused on developing and commercializing novel therapies for serious liver disease, with a particular emphasis on metabolic dysfunction-associated steatohepatitis, or MASH. Madrigal’s corporate story dates back to the early 2000s, when founder Rebecca Taub, M.D., began applying her expertise in liver biology to identify a therapeutic approach centered on thyroid hormone receptor beta (THR-β). The company’s headquarters are in Conshohocken, Pennsylvania, United States.
Madrigal is best understood as a highly focused specialty biopharma rather than a diversified pharmaceutical group. Its commercial engine is anchored by Rezdiffra (resmetirom), a once-daily oral therapy designed for adults with noncirrhotic MASH and moderate to advanced liver fibrosis (F2 to F3). Rezdiffra has become the company’s defining asset: it received accelerated approval from the U.S. FDA and later conditional authorization from the European Commission, making it the first and only approved medicine in this specific MASH setting. That approval profile gives Madrigal a first-mover advantage in a market that remains underpenetrated but potentially very large, where physician education, reimbursement access, and long-term clinical differentiation will be critical.
Read moreShow less
From a competitive perspective, Madrigal occupies an important position in one of the most closely watched therapeutic areas in metabolic and liver disease. MASH has attracted strong interest from large pharma and emerging biotech peers because of the size of the unmet need, the chronic nature of the disease, and the opportunity to treat patients before progression to cirrhosis or liver failure. Madrigal’s current edge lies in being commercially ahead of most direct competitors, with an approved product, real-world launch execution, and growing clinical data supporting the franchise.
Geographically, the business has historically been U.S.-centric, but it is now expanding into Europe following regulatory clearance there. This is strategically important because it broadens the addressable market and reduces reliance on a single geography. For international investors, especially in French-speaking markets, Madrigal is therefore not just a U.S. biotech story but an emerging transatlantic liver-disease franchise.
Recent company updates point to a more ambitious pipeline strategy. In 2026, Madrigal reported accelerating Rezdiffra sales and continued to expand its development platform through licensing agreements spanning oral GLP-1, DGAT-2, and siRNA programs. The strategic message is clear: Madrigal is seeking to evolve from a single-product launch story into a broader MASH-focused therapeutic platform. That makes the investment case more nuanced, combining commercial execution on Rezdiffra with pipeline optionality and execution risk typical of growth-stage biopharma.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
